Although p53 in mass cytometry was briefly explored previously [20], here we present mass cytometry as a tool that enables assessment of the p53 expression, including post-translational modification (acetylation at K382) and downstream targets, in various cancer cells, focusing on the aggressive bone marrow-derived cancer AML. Here, TP53 is linked to acute myeloid leukemia.